Brain Imaging Biomarkers in Patients With Brain Metastasis

Recruiting now · Phase 2

Conditions studied: Brain Metastases, Adult

In brief

A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.

Key facts

Study ID

NCT04197297

Run by

University Health Network, Toronto

People needed

90

Starts

2021-10-05

Expected to finish

2027-06-01

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
• At least one index lesion with diameter > 1cm and without imaging evidence of hemorrhage
• Patients age > 18 years of age
• Patients planned for RT to brain metastases
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Previous Whole Brain Radiotherapy
• Previous radiosurgery to the index lesion
• Individuals unable to undergo contrasted MRI for whatever reason

Where it is running

• University Health Network — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.